Key Finding
Moxibustion therapy significantly reduced total cholesterol, LDL, triglycerides, apolipoprotein B, and fasting blood sugar in patients with hyperlipidemia, though it did not significantly affect HDL or apolipoprotein A-I levels.
Researchers recently analyzed multiple studies to determine whether moxibustion—a traditional Chinese medicine therapy that involves burning dried mugwort herb near the skin—can help people with high cholesterol and elevated blood fats (hyperlipidemia). The review examined six studies including 228 patients with hyperlipidemia who received moxibustion treatment.
The analysis found that moxibustion therapy led to significant improvements in several important blood markers. After treatment, patients showed meaningful reductions in total cholesterol, LDL ("bad" cholesterol), triglycerides, apolipoprotein B, and fasting blood sugar levels. These are all key indicators that doctors monitor when assessing cardiovascular health risk. However, the therapy did not significantly increase HDL ("good" cholesterol) or apolipoprotein A-I levels.
What this means for patients: This research suggests that moxibustion may be a beneficial complementary therapy for managing high cholesterol and lipid levels. The improvements seen in multiple blood markers indicate that moxibustion could positively affect fat metabolism in the body. This is encouraging news for people looking for integrative approaches to cardiovascular health alongside conventional treatments.
However, the researchers noted some limitations. The studies analyzed were relatively small, and more high-quality research is needed to determine optimal treatment protocols and fully understand safety considerations, especially for high-risk patients. The positive findings support considering moxibustion as part of a comprehensive treatment plan for hyperlipidemia, though it should complement rather than replace standard medical care. If you're interested in trying moxibustion for cholesterol management, seek treatment from a qualified, licensed acupuncturist trained in traditional Chinese medicine techniques.
This systematic review and meta-analysis evaluated moxibustion (MXB) efficacy for hyperlipidemia treatment across six randomized controlled trials involving 228 patients (25.43% male, 51.75% female). Using random-effects models, researchers assessed pre- and post-treatment lipid profiles, apolipoproteins, and fasting blood sugar.
Results demonstrated statistically significant improvements in multiple parameters: TC (OR=0.69, p=0.02), LDL (OR=0.42, p<0.001), TG (OR=0.35, p<0.001), Apo B (OR=0.33, p=0.02), and FBS (OR=0.38, p=0.02). No significant changes were observed in HDL (OR=-0.16, p=0.16) or Apo A-I (OR=0.01, p=0.96).
Clinical Takeaway: This meta-analysis provides evidence supporting MXB as an adjunctive therapy for hyperlipidemia management, demonstrating significant improvements in atherogenic lipid markers and glycemic control. The positive correlation between MXB therapy and improved lipid metabolism supports clinical application for appropriate patients. However, practitioners should note study limitations including small sample sizes and lack of comprehensive safety data. Additional high-quality trials with standardized dosing protocols and longer follow-up periods are needed before definitive treatment guidelines can be established.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Different moxibustion temperatures activate distinct thermosensitive proteins and pathways that influence the phenotypic remodeling of primary lesion cells in rheumatoid arthritis, including fibroblast-like synoviocytes, macrophages, and T cells.
📌 Moxibustion significantly reduced arthritis severity in animal models with large effect sizes (SMD -3.72 for arthritis index) while suppressing pro-inflammatory cytokines and key signaling pathways including NF-κB and NLRP3 inflammasome.
📌 Three transdermal moxibustion compounds—Citral, α-Terpineol, and Borneol—were identified as targeting TNF-α to reduce rheumatoid arthritis through MAPK pathway inhibition and MMP modulation.